Johnson & Johnson : Janssen Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of BALVERSA® (erdafitinib) for the Treatment of Patients with Locally Advanced or Metastatic Urothelial Carcinoma and Selected Fibroblast Growth Factor Receptor Gene Alterations -Today at 09:18 am
News Release Media Contacts: Suzanne Frost Phone: +1 416-317-0304 Ania DiAntonio ...
Peter Lebowitz Ania Diantonio Drug Administration Astex Pharmaceuticals Administration Seeking Full Approval American Society Of Clinical Oncologyannual Meeting
Source: marketscreener.com